Cancer incidence in patients with a high normal platelet count: a cohort study using primary care data.
Ankus, E; Price, S; Ukoumunne, OC; et al.Hamilton, W; Bailey, S
Date: 12 April 2018
Journal
Family Practice
Publisher
Oxford University Press (OUP)
Publisher DOI
Abstract
Background
A platelet count >400×109/l (i.e. thrombocytosis) is a recently discovered risk marker of cancer. The risk of undiagnosed cancer in patients with thrombocytosis is 11.6% for men and 6.2% for women; well above the 3% risk threshold set by NICE for cancer investigation. Patients with a platelet count at the upper end of the ...
Background
A platelet count >400×109/l (i.e. thrombocytosis) is a recently discovered risk marker of cancer. The risk of undiagnosed cancer in patients with thrombocytosis is 11.6% for men and 6.2% for women; well above the 3% risk threshold set by NICE for cancer investigation. Patients with a platelet count at the upper end of the normal range (325-400x109/l) could be at increased risk of undiagnosed malignancy.
Objective
To quantify the risk of an undiagnosed cancer in patients with a platelet count at the upper end of the normal range.
Methods
A primary care-based cohort study using Clinical Practice Research Datalink (CPRD) data from 2000 - 2013. The study sample comprised 2704 individuals stratified by platelet count: 325-349 x 109/l; 350-374 x 109/l; 375-399 x 109/l. Incident cancer diagnoses in the year following that platelet count were obtained from patient records.
Results
Cancer incidence rose with increasing platelet count: 2.6% (95% CI 1.9 to 3.6) in subjects with a count of 325-349x109/l; 3.7% (95% CI 2.5 to 5.3) in subjects with a count of 350-374x109/l; and 5.1% (95% CI 3.4 to 7.5) in those with a count of 375-399x109/l. Colorectal cancer was the most commonly diagnosed type in all three groups. Cancer incidence was consistently higher in males than in females.
Conclusion
These results suggest that clinicians should consider cancer in patients with a platelet count >375x109/l, and review the reasons for blood testing and any additional reported symptoms. Until these results are replicated on a larger scale, recommendations for clinical action cannot be made.
Institute of Health Research
Collections of Former Colleges
Item views 0
Full item downloads 0